Dianthus Begin Period Cash Flow from 2010 to 2024
| DNTH Stock | 23.99 0.16 0.67% |
Begin Period Cash Flow | First Reported 2017-03-31 | Previous Quarter 329.7 M | Current Value 62.6 M | Quarterly Volatility 65.9 M |
Check Dianthus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dianthus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 337.2 K, Interest Expense of 2.7 M or Selling General Administrative of 14.9 M, as well as many indicators such as Price To Sales Ratio of 18.02, Dividend Yield of 0.0 or PTB Ratio of 0.3. Dianthus financial statements analysis is a perfect complement when working with Dianthus Therapeutics Valuation or Volatility modules.
Dianthus | Begin Period Cash Flow |
Latest Dianthus Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Dianthus Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Dianthus Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dianthus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Dianthus Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 15,288,480 | |
| Geometric Mean | 3,236,839 | |
| Coefficient Of Variation | 151.80 | |
| Mean Deviation | 17,938,773 | |
| Median | 2,663,000 | |
| Standard Deviation | 23,207,995 | |
| Sample Variance | 538.6T | |
| Range | 64.6M | |
| R-Value | 0.44 | |
| Mean Square Error | 469.3T | |
| R-Squared | 0.19 | |
| Significance | 0.10 | |
| Slope | 2,267,459 | |
| Total Sum of Squares | 7540.6T |
Dianthus Begin Period Cash Flow History
About Dianthus Therapeutics Financial Statements
Investors use fundamental indicators, such as Dianthus Therapeutics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Dianthus Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 15.4 M | 20.6 M |
Currently Active Assets on Macroaxis
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out the analysis of Dianthus Therapeutics Correlation against competitors. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 7.22 | Revenue Per Share 0.19 | Quarterly Revenue Growth 1.351 | Return On Assets (0.19) | Return On Equity (0.26) |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.